Amit Verma, MD
Internal Medicine · Dallas, TXNPI 1033299524
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,013 of the $52,970 with a category attached, or 86.9%. 15 manufacturers reported payments, led by Janssen Research & Development, LLC at 51.1% of the total. Reporting peaked in 2022 at $20,141 and has fallen 99.1% since, to $184 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $1471.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$27K
- E.r. Squibb & Sons, L.L.C.$8K
- Gilead$6K
- Novartis$4K
- Bristol Myers Squibb$4K
- Astrazeneca UK Limited$3K
- plus $2K from 9 others
Across 149 payments — averaging $51,611 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6.1M
- Janssen Research & Development, LLC$1.1M
- Bristol Myers Squibb$162K
- Pfizer$105K
- Otsuka Pharmaceutical Co., Ltd.$59K
- Takeda Pharmaceuticals U.S.A., Inc.$36K
- plus $113K from 6 others
What the payments were for
- Consulting fees$46,01387%
- Speaking & faculty fees$1,2702%
- Travel & lodging$5671%
- Food & beverage$4501%
- Education$4,6719%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $27,060 |
| E.r. Squibb & Sons, L.L.C. | 2 | $8,131 |
| Gilead(2 entities) | 8 | $5,998 |
| Novartis | 2 | $3,780 |
| Bristol Myers Squibb | 2 | $3,703 |
| Astrazeneca UK Limited | 1 | $2,740 |
| Pfizer | 2 | $1,270 |
| Geron Corporation | 3 | $143 |
| Medtronic | 1 | $41 |
| Deciphera Pharmaceuticals Inc. | 1 | $27 |
| AstraZeneca | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $15 |
| Sanofi | 1 | $12 |
| Incyte Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,970 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Dallas
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Han SchmidlyDallas$465K
- Athica VatanapradithDallas$164K
- Nicholaos BellosDallas$113K
- Steven HeldDallas$65K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Mohammed Al-NajjarEl Paso$586K
- Hussein TawbiHouston$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.